Shilpa Medicare's Profit More Than Triples as Margins Expand Sharply
The API maker's Q1 profit jumped 247% year-on-year, though revenue and profit dipped sequentially from a strong Q4.
Shilpa Medicare's first-quarter profit surged 247% year-on-year, driven by a massive expansion in net profit margin. Revenue also more than doubled compared to the same period last year.
Shilpa Medicare has kicked off FY27 with explosive profit growth, more than tripling its bottom line compared to a year ago. This remarkable surge was powered by a significant expansion in profitability, even as the company's top and bottom lines moderated from the previous quarter's peak.
The API and formulations maker reported a profit of ₹64.92 crore for the quarter ended June 2026, a 247% leap from the ₹18.71 crore earned in Q1 FY26. Revenue more than doubled year-on-year, rising 102.3% to ₹189.04 crore. The most telling figure is the net profit margin, which expanded by a massive 1,430 basis points to 34.3%, up from 20.0% a year ago. This indicates the company is converting a much larger portion of its sales into profit.
However, the quarter saw a sequential pullback. Revenue declined 6.0% from ₹201.11 crore in Q4 FY26, while profit fell 8.5% from ₹70.96 crore. The trailing-twelve-month (TTM) net profit margin stands at 26.4%, suggesting the latest quarter's margin, while strong, is above the recent average.
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin
| Metric | CurrentQ1 FY27 | PreviousQ4 FY26 | Same quarter LYQ1 FY26 |
|---|---|---|---|
| Period | Quarter ended June 2026 | Quarter ended March 2026 | Quarter ended June 2025 |
| Revenue (₹ Cr) | 189.04YoY +102% | 201.11 | 93.46 |
| Profit (₹ Cr) | 64.92YoY +247% | 70.96 | 18.71 |
| Net Profit Margin | 34.3%YoY +71% | 35.3% | 20.0% |
The table highlights the company's dramatic earnings trajectory over the past year, with profitability strengthening considerably in the last two quarters. The stock has faced recent pressure, down 10.1% over the past year, but has delivered a robust 102.2% return over three years. At a P/E of 82.8, the valuation commands a significant premium to the industry average of 37.2, reflecting high expectations for its growth and margin profile.
Maintaining profitability near these elevated levels will be the key challenge as Shilpa Medicare progresses through the fiscal year.
Live Chart
· SHILPAMED
(BSE)
ISIN: INE790G01031
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.